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Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with
C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe.
Aim: To compare the economic impact of two icatibant administration strategies: health professional-
administration only (strategy 1) versus including the patient self-administration option (strategy 2).
Methods: Economic evaluation model based on the building of a decision tree. Both strategies are assumed to
have equivalent effectiveness. The payer (Spanish National Health System) and the social perspectives were
considered. All relevant cost-generating factors were taken into account. The time horizon was one year. Sources of
information included scientific evidence, official data and experts’ opinion. A deterministic sensitivity analysis was
carried out to quantify the underlying uncertainty in the model.
Results: From the social perspective, which considers both direct (health care costs) and indirect costs (productivity
losses), strategy 2 would result into average savings of €121.30 per acute attack compared to strategy 1. For Spain,
this would achieve in an annual savings of €551,371. The reduction in direct costs accounts for 74% of the savings
and lower indirect costs account for the remaining 26%. Savings per acute attack may range from €79.50 to
€169.80; accordingly, the annual savings in Spain may vary between €90,319 and €2,315,360.
Conclusion: Costs related to the management of acute HAE attacks with C1 inhibitor deficiency may be
substantially reduced through interventions targeting home treatment by training patients to self-administer
icatibant.
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Hereditary angioedema with C1-esterase inhibitor defi-
ciency (HAE-C1-INH) is an autosomal dominant heredi-
tary disease caused by deficiency or dysfunction of the
protein C1-esterase inhibitor (C1-INH) [1,2]. The de-
crease in C1-INH activity may increase plasma concen-
tration of bradykinin, the key mediator of HAE-C1-INH
symptoms. Patients with this condition experience recur-
rent episodes of oedema in subcutaneous tissue or sub-
mucosa. Areas affected by this swelling include upper
respiratory tract, face, limbs, genitals, and digestive tract* Correspondence: ablasco@taiss.com
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Attribution License (http://creativecommons.or
in any medium, provided the original work is p[1,2]. Laryngopharyngeal oedema may be life-threatening
due to upper respiratory tract obstruction [3,4].
Icatibant acetate (FirazyrW, Shire HGT), a selective
bradykinin B2 receptor competitive antagonist, is among
the therapies available for acute HAE-C1-INH attacks
[5,6]. Recommended dosage to treat HAE-C1-INH epi-
sodes is a 30 mg subcutaneous injection, preferably in the
abdomen [7]. A recent clinical study, named “Evaluation
of the Safety of Self-Administration with Icatibant
(EASSI)”, evaluated the safety, tolerability, convenience,
and effectiveness of FirazyrW self-administration [8]. Based
on the study’s favourable results, the European Medicines
Agency (EMA) has recently approved FirazyrW self-
administration for appropriately trained patients in the
drug’s self-administration technique [9]. Icatibant is then Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Patient’s self-administration of icatibant may reduce
healthcare costs and may improve the drug’s effectiveness
due to the accessibility of the treatment. Additionally, by
reducing the need of health centres or emergency services
visits, the patient would miss fewer hours of work, study,
or leisure time.
To our knowledge, there is a lack of evaluation studies
comparing icatibant administration methods. This study
was designed to fill that gap and compare the economic
costs of two strategies to manage acute HAE-C1-INH
attacks in Spain. The first strategy assumes that only
healthcare professionals administer the drug (health
professional-only administration) and the second strat-
egy contemplates that, in addition to visiting a health pro-




This economic evaluation study was developed by build-
ing a deterministic decision tree model with sensitivity
analysis. The theoretical model compares the costs of
health professional-only administration (strategy 1) vs.
the costs of self-administration option (strategy 2). Since
the model assumes that both strategies are equally ef-
fective [8,10,11], this is a cost-minimization study. Ana-
lyses were performed from two different perspectives:
The payer (Spanish National Health System) perspective
which considers direct costs only; and the social per-
spective which considers both direct and indirect costs.
Indirect costs are defined as those incurred from labour
productivity losses (lost working hours). The time hori-
zon is one year.
Model building
The model was built in two phases: 1) Decision tree
structure; and 2) Values assignation (probabilities and
possible values for cost variables). For building the deci-
sion tree, the sequence of events was established, and
the cost-generating variables and the categories for each
variable for each of the two strategies were defined
(Table 1). Variables were defined as follows: Attack se-
verity: mild (discomfort that does not disrupt regular
daily activities); moderate (discomfort that reduces or
impacts regular daily activities); and severe (symptoms
preventing work or daily activities) [1]. Episode duration
is the time between the onset of symptoms and their
complete resolution. Length of stay is the time patients
spend in a healthcare facility. Labour force participation
categories are: Employed, Unpaid household work and
Other (unemployed, students, retired or early retirees
due to permanent disability, recipients of pensions otherthan retirement or early retirement, volunteers in social
work, charity organizations, and other [12]). Since
icatibant is not approved for younger than 18 years, the
age category “under 18” was not considered. The final
product was a decision tree structure applicable to HAE
episode management for the two treatment strategies.
Figure 1 shows a simplified model of the decision tree.
During the second phase, the model content was com-
pleted assigning probabilities to each of the variables’ cat-
egories, and allocating values to the model’s cost variables.
Probability assignment
Probabilities were assigned based on the best available
scientific evidence. In some cases, data were not avail-
able or were available for other populations and, thus,
the experts (TC, MG) deemed them inappropriate for
modelling Spanish events. In these cases, the assignment
of probabilities was informed by experts’ opinions.
Official data sources were used for the age variable
(Spain’s population as of April 1st, 2011 [13]) and for
the labour participation variable (Labour Force Survey,
First Quarter, 2011 [12]).
Experts’ opinions informed the parameterization of the
remaining variables by assigning estimates of average,
maximum, and minimum values for each variable. The
experts parameterized the variables anonymously in two
separate rounds with no interaction during the first
round. The mean of these estimates became the synthe-
sis estimators and during the second round the final
values were allocated by consensus.
Cost allocation
The payer’s perspective accounts only for direct medical
costs (treatment, hospital emergency room visit, primary
care emergency room visit, HAE specialist visit, hospital
admission, ICU admission, and tracheotomy) and non-
medical costs (transportation).
Because the healthcare system in Spain is governed by
the autonomous communities (AC) (political geographic
divisions), there are not national prices. Thus, a resource
unit cost based on the official AC lists of resource unit
costs [14-31] was estimated. This cost was calculated as
the average price for healthcare services rendered by the
AC Departments of Health. Treatment cost was the
pharmaceutical laboratory sale’s price (LSP) plus the value
added tax (VAT).
Transportation costs were estimated using data from
the Centro de Estudios y Experimentación de Obras
Públicas (CEDEX) (Center for Public Works Studies and
Experimentation) [32]. CEDEX provides estimates of the
cost per kilometre of private transportation taking into
account the investment, maintenance, vehicle repairs, tires
change, insurance policy, motor vehicle tax, gasoline,
parking, fines, and tolls.
Table 1 Variables included in the model
Value
Variable Average Minimum Maximum
Age (number of residents)
18-64 years 29,963,795
≥ 65 years 7,914,361
Work status (%)
Employed 59.88%
Unpaid household work 8.78%
Other 31.34%
HAE Prevalence per 100,000 persons 2.00 1.00 4.00





Episode duration with strategy 1 (hours)
Mild 15.00 13.00 18.00
Moderate 10.00 8.00 12.00
Severe 17.00 14.00 21.00




Episode duration with strategy 2 (hours)
Mild 7.50 6.50 9.00
Moderate 4.00 3.20 4.80
Severe 5.10 4.20 6.30
With strategy 1, a mild episode results in (%)
Hospital emergency room visit 2.00% 1.00% 3.00%
Primary care emergency room visit 3.00% 2.00% 4.00%
HAE specialist office visit 2.00% 1.00% 3.00%
No emergency visit 93.00% 96.00% 90.00%
With strategy 1, a moderate episode results in (%)
Hospital emergency room visit 70.00% 60.00% 80.00%
Primary care emergency room visit 5.00% 3.00% 7.00%
HAE specialist office visit 10.00% 7.00% 12.00%
No emergency visit 15.00% 30.00% 1.00%
With strategy 1, a severe episode results in (%)
Hospital emergency room visit 87.00% 85.00% 89.00%
Primary care emergency room visit 2.00% 1.00% 3.00%
HAE specialist office visit 9.00% 6.00% 8.00%
No emergency visit 2.00% 8.00% 0.00%
With strategy 2, a mild episode results in (%)
Hospital emergency room visit 0.00% 0.00% 0.00%
Primary care emergency room visit 0.00% 0.00% 0.00%
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Table 1 Variables included in the model (Continued)
HAE specialist office visit 0.00% 0.00% 0.00%
No emergency visit 100.00% 100.00% 100.00%
With strategy 2, a moderate episode results in (%)
Hospital emergency room visit 10.00% 7.00% 12.00%
Primary care emergency room visit 1.00% 0.00% 2.00%
HAE specialist office visit 3.00% 1.00% 5.00%
No emergency visit 86.00% 92.00% 81.00%
With strategy 2, a severe episode results in (%)
Hospital emergency room visit 15.00% 12.00% 18.00%
Primary care emergency room visit 1.00% 0.00% 2.00%
HAE specialist office visit 4.00% 2.00% 6.00%
No emergency visit 80.00% 86.00% 74.00%
Length of stay in hospital emergency room (hours)
Mild 4.0 3.0 6.0
Moderate 7.0 5.0 9.0
Severe 16.0 12.0 20.0
Length of stay in primary care emergency room (hours)
Mild 2.0 1.0 3.0
Moderate 4.0 3.0 5.0
Severe 6.0 4.0 8.0
Length of stay at the HAE specialist (hours)
Mild 1.5 1.0 2.0
Moderate 2.0 1.0 3.0
Severe 5.0 4.0 6.0
Round trip distance to healthcare facility (Km)
To hospital 30.00 20.00 40.00
To primary care centre 4.00 2.00 6.00
Round trip travel time (minutes)
To hospital 45.00 30.00 60.00
To primary care centre 15.00 10.00 20.00
Timing of episodes among gainfully employed (%)
Work hours 21.92%
Non work hours 78.08%
Timing of episodes among unpaid homemakers (%)
Work hours 30.59%
Non work hours 69.41%
% episode duration during which unable to work
Mild 0.00% 0.0% 0.0%
Moderate 40.00% 30.0% 50.0%
Severe 80.00% 70.0% 90.0%
Probability (%) patient comes with a caretaker (by age group and episode severity)
18-64 years/mild 50.0% 40.0% 60.0%
18-64 years/moderate 60.0% 50.0% 70.0%
18-64 years/severe 95.0% 90.0% 100.0%
≥ 65 years/mild 70.0% 60.0% 80.0%
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Table 1 Variables included in the model (Continued)
≥ 65 years/moderate 80.0% 70.0% 95.0%
≥ 65 years/severe 95.0% 90.0% 100.0%
% of episode duration patient requires caretaker (by age group and episode severity)
18-64 years/mild 0.0% 0.0% 0.0%
18-64 years/moderate 20.0% 15.0% 30.0%
18-64 years/severe 70.0% 60.0% 80.0%
≥ 65 years/mild 0.0% 0.0% 0.0%
≥ 65 years/moderate 40.0% 30.0% 50.0%
≥ 65 years/severe 80.0% 70.0% 90.0%
Icatibant syringes per episode
Mild 1.00 0.90 1.10
Moderate 1.10 1.00 1.20
Severe 1.10 1.00 1.30
With strategy 1, during a severe episode the probability (%) of:
Death 0.01% 0.005% 0.015%
Tracheotomy 0.20% 0.10% 0.30%
Hospital admission 0.40% 0.30% 0.50%
Length of admission for severe episode (days):
General ward 2.00 1.00 3.00
ICU 2.00 1.00 3.00
With strategy 2, during a severe episode the probability (%) of:
Death 0.0010% 0.0005% 0.0015%
Tracheotomy 0.0200% 0.0100% 0.0300%
Hospital admission 0.1000% 0.0500% 0.1500%
Icatibant administration: Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
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indirect costs. Indirect costs are defined as patient’s and
caretaker’s working hours lost per episode plus working
hours lost in case of patient’s death. Leisure time lost was
not included in the calculation. For employed workers,
labour cost was estimated using the human capital
method, based on the cost of the working hour reported
in the Quarterly Survey of Labour Costs during the Fourth
Quarter of 2010 [33]. For unpaid work (household work)
the substitution cost method was used.
The cost of lost labour due to the patient’s death was
estimated multiplying the years the patient would no
longer contribute to the national wealth (contributing
years lost) times the per capita gross domestic product
(GDP). The per capita GDP was calculated dividing the
national 2009 GDP (last available datum) [34] by the
Spanish population count as of July 1st, 2009 [13]. To
calculate contributing years lost, it was assumed that, in
average, patients under 65 years-old die at 41.5 years of
age. For those 65 and over, death occurs half way
between 65 and life expectancy at 65. The amount of
contributing years lost is the difference between life ex-
pectancy [35] and age at death.The product of this phase was the final model: a deci-
sion tree loaded with the probability values and the costs
associated with each path.
Sensitivity analysis
A sensitivity analysis was performed to evaluate the under-
lying uncertainty dependent on the variability in the ex-
perts’ estimators and the resources unit costs. Three
scenarios were built under this analysis: base case scenario;
most favourable (for strategy 2 vs. strategy 1); and least
favourable (for strategy 2 vs. strategy 1). Unit costs for re-
sources were allowed a potential variability of ± 5%.
Base case scenario employs the average unit costs and
the average experts’ estimators. The most favourable sce-
nario uses the maximum unit costs and maximum ex-
perts’ estimators, except for the following variables in
strategy 2: Facility in which episode is treated, probability
of death given a severe episode, probability of tracheotomy
given a severe episode, and probability of admission given
a severe episode for which the minimum estimators were
entered. For the least favourable scenario the minimum
unit costs and minimum experts’ estimators were con-
sidered, except for the variables mentioned above in
Table 2 Unit costs of resources used in 2011
Variable Cost (€) Unit
Direct costs
Medical
Icatibant 1,762.80 syringe 30 mg




HAE specialist 131.67 visit
General ward admission 443.61 day





Employee loss labour 17.27 hour



































Figure 1 Simplified model of decision tree. Icatibant administration: Strategy 1= Health professional-administration only; Strategy 2= Self-
administration also available. HAE: Hereditary angioedema. ER: Emergency room.
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entered.
Results
Table 1 shows the values assigned to the variables in the
model. Table 2 shows unit costs of the resources included
in the model.
In the base case scenario, HAE-C1-INH prevalence is
2 per 100,000 persons and each patient suffers an aver-
age of 6 acute attacks per year. Consequently, it is esti-
mated that in Spain there would be 758 HAE-C1-INH
patients experiencing a total of 4,545 acute attacks per
year. Using the social perspective, the average cost of
managing one of these episodes with strategy 1 (health
professional-administration) would be €1,315.14 versus
€1,193.84 with strategy 2 (self-administration option).
This translates into an average savings of €121.30 (9.2%
cost reduction) per episode with strategy 2, representing
an annual saving of €551,371 nationwide. A reduction in
direct costs would account for 74% of the savings and a
decrease in indirect costs would make up the remaining
26% of the money saved. With the payer perspective, the
average savings per episode would be €89.8 (7%), which
Table 3 Cost of managing HAE episodes with icatibant (Euros)
Per episode Nationwide per year
Variable Strategy 1 Strategy 2 Savings Strategy 1 Strategy 2 Savings Savings (%)
Direct costs 1,272.42 1,182.62 89.80 5,783,612 5,375,455 408,157 7.06
Medical 1,264.71 1,181.31 83.40 5,748,578 5,369,480 379,098 6.59
Icatibant 1,164.95 1,164.95 0.00 5,295,122 5,295,122 0 0.00
Visits* 97.13 16.22 80.92 441,498 73,706 367,792 83.31
Admissions 2.44 0.12 2.32 11,113 567 10,546 94.90
Tracheotomy 0.19 0.02 0.17 845 84 760 90.00
Non-medical 7.71 1.31 6.39 35,034 5,975 29,059 82.95
Transportation 7.71 1.31 6.39 35,034 5,975 29,059 82.95
Indirect costs 42.73 11.22 31.51 194,220 51,006 143,214 73.74
Caretaker 13.54 4.81 8.73 61,535 21,844 39,691 64.50
Labour loss 13.63 4.86 8.77 61,967 22,090 39,877 64.35
Death 15.56 1.56 14.00 70,718 7,072 63,646 90.00
Social cost 1,315.14 1,193.84 121.30 5,977,832 5,426,461 551,371 9.22
Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
*Includes visits to hospital emergency rooms, primary care centres emergency rooms, and to HAE specialist offices.
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wide. The decrease in healthcare services use (emergency
services and visits to specialists) accounts for the bulk of
the savings (Table 3).
The number of episodes and the average treatment
cost (with the social perspective), according to patient’s
age and severity of the attack is showed in Table 4. The
more severe the episode, the greater the savings are. Sav-
ings are also greater in patients under 65 than in those
65 and over, due to the greater reduction in indirect
costs.
Sensitivity analysis
In the most favourable scenario for strategy 2, HAE-C1-
INH prevalence is 4 per 100,000 persons and each pa-
tient experiences an average of 9 acute attacks per year.Table 4 Number of episodes and average cost (Euros) based o
episode severity












Strategy 1= Health professional-administration only; Strategy 2= Self-administrationThis would add up to 1,515 patients suffering a total of
13,636 acute attacks per year. Under the social pers-
pective, the average cost of managing an episode would
be €1,664.21 with strategy 1 and €1,494.41 with strategy 2.
Therefore, strategy 2 (self-administration option) would
save an average of €169.80 (10.2%) per episode (Table 5)
which would translate into an annual saving of €2,315,360
nationwide. The reduction in direct costs would account
for 70% of the savings and a decrease in indirect costs
would explain the remaining 30% (Table 6). With the
payer perspective, the average savings would be €119.21
(7.5%) which represent an annual saving of €1,625,616
nationwide.
In the least favourable scenario for strategy 2, HAE-
C1-INH prevalence is 1 per 100,000 persons and each
patient suffers an average of 3 acute attacks per year.n the social perspective, according to age group and
Cost (€)
egy 1 Strategy 2 Savings (€) Savings (%)
133.8 123.4 10.43 7.80
,826.3 1,681.6 144.76 7.93
,262.2 1,976.2 285.99 12.64
,321.1 1,195.1 125.99 9.54
133.4 123.4 10.01 7.51
,812.3 1,677.7 134.52 7.42
,151.5 1,953.9 197.59 9.18
,292.5 1,189.0 103.56 8.01
,315.1 1,193.8 121.30 9.22
also available.
Table 5 Average cost of managing HAE episodes with icatibant (Euros)
Most favourable scenario Least favourable scenario
Variable Strategy 1 (€) Strategy 2 (€) Savings (€) Savings (%) Strategy 1 (€) Strategy 2 (€) Savings (€) Savings (%)
Direct costs 1,600.16 1,480.94 119.21 7.45 986.69 923.07 63.62 6.45
Medical 1,588.12 1,479.73 108.39 6.82 982.48 922.00 60.48 6.16
Icatibant 1,468.59 1,468.59 0.00 0.00 901.85 901.85 0.00 0.00
Visits* 114.33 11.07 103.26 90.32 79.54 20.07 59.47 74.77
Admissions 4.91 0.07 4.84 98.60 0.82 0.05 0.77 93.78
Tracheotomy 0.29 0.01 0.28 96.67 0.26 0.03 0.24 90.00
Non-medical 12.03 1.21 10.82 89.95 4.21 1.08 3.14 74.47
Transportation 12.03 1.21 10.82 89.95 4.21 1.08 3.14 74.47
Indirect costs 64.05 13.47 50.58 78.97 25.21 9.34 15.87 62.95
Caretaker 20.56 6.47 14.09 68.53 8.62 3.49 5,14 59.55
Labor loss 18.98 6.18 12.80 67.45 9.19 3.63 5.56 60.46
Death 24.50 0.82 23.69 96.67 7.39 2.22 5.17 70.00
Social costs 1,664.21 1,494.41 169.80 10.20 1,011.89 932.41 79.48 7.85
Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
*Includes visits to hospital emergency rooms, primary care centres emergency rooms, and to HAE specialist offices.
Sensitivity analysis.
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of 1,136 acute attacks per year. Under the social per-
spective, the average cost of managing an episode would
be €1,011.89 with strategy 1 and €932.41 with strategy 2.
Thus, strategy 2 yields an average savings of €79.48 per
episode (7.9%) (Table 5). This leads to an annual saving
of €90,319 nationwide. Direct costs reduction would
account for 80% of the savings and a decrease in indirect
costs would explain the remaining 20% (Table 6). Using
the payer perspective, the average saving per episodeTable 6 Nationwide annual cost of managing HAE episodes w
Most favourable scenario
Variable Strategy 1 (€) Strategy 2 (€) Savings (€) Sav
Direct costs 21,819,956 20,194,340 1,625,616
Medical 21,655,858 20,177,846 1,478,012
Icatibant 20,025,875 20,025,875 0
Visits* 1,559,016 150,900 1,408,116
Admissions 66,974 938 66,037
Tracheotomy 3,992 133 3,859
Non-medical 164,099 16,494 147,604 8
Transportation 164,099 16,494 147,604
Indirect costs 873,371 183,627 689,743 7
Caretaker 280,398 88,246 192,152
Labor loss 258,830 84,243 174,587
Death 334,142 11,138 323,004
Social costs 22,693,327 20,377,967 2,315,360 1
Strategy 1= Health professional-administration only; Strategy 2= Self-administration
*Includes visits to hospital emergency rooms, primary care centres emergency room
Sensitivity analysis.would be €63.62 (6.5%) which would represent an an-
nual saving of €72,289 nationwide.
Table 7 shows the number of episodes and the average
treatment cost (with the social perspective) according to
patient’s age and severity of the attack, for the most and
least favourable scenarios.
In summary, the cost comparison between strategy 2
and 1, shows that with the social perspective, savings per
episode would be of €121.3 that could range from €79.5
to €169.8. This equals to save the 9.2% of the costs,ith icatibant (Euros)
Least favourable scenario
ings (%) Strategy 1 (€) Strategy 2 (€) Savings (€) Savings (%)
7.45 1,121,218 1,048,929 72,289 6.45
6.82 1,116,431 1,047,707 68,723 6.16
0.00 1,024,811 1,024,811 0 0.00
90.32 90,390 22,808 67,581 74.77
98.60 929 58 871 93.78
96.67 301 30 271 90.00
9.95 4,787 1,222 3,565 74.47
89.95 4,787 1,222 3,565 74.47
8.97 28,643 10,613 18,030 62.95
68.53 9,800 3,964 5,837 59.55
67.45 10,445 4,130 6,315 60.46
96.67 8,398 2,519 5,878 70.00
0.20 1,149,861 1,059,542 90,319 7.85
also available.
s, and to HAE specialist offices.
Table 7 Number of episodes and average cost (Euros) with the social perspective, according to age group and episode
severity























Mild 3,775 210.7 193.9 16.8 7.98 315 68.7 63.5 5.2 7.59
Moderate 4,854 2,325.1 2,122.8 202.3 8.70 405 1,365.6 1,269.4 96.2 7.04
Severe 2,157 2,764.7 2,363.6 401.1 14.51 180 1,883.9 1,700.6 183.3 9.73
Total 10,787 1,673.0 1,495.9 177.2 10.59 899 1,015.3 933.6 81.8 8.05
≥ 65
years
Mild 997 209.8 193.9 15.9 7.58 83 68.5 63.5 5.1 7.40
Moderate 1,282 2,304.9 2,117.6 187.3 8.13 107 1,357.2 1,266.7 90.6 6.67
Severe 570 2,601.0 2,340.8 260.3 10.01 47 1,820.4 1,678.9 141.6 7.78
Total 2,849 1,630.9 1,489.0 141.9 8.70 237 998.8 928.0 70.8 7.09
TOTAL 13,636 1,664.2 1,494.4 169.8 10.20 1,136 1,011.9 932.4 79.5 7.85
Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
Sensitivity Analysis.
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reduction in Spain would be of €551,371 ranging from
€90,319 to €2,315,360.
With the payer perspective, savings per episode would
be €89.80 that could range from €63.60 to €119.20. This
equals to a savings of 7% which could range from 6.5%
to 7.5%. Annual cost reduction in Spain would be
€408,157 ranging between €72,289 and €1,625,616.
Discussion
According to this study’s findings, the possibility of pa-
tients self-administering icatibant to control acute HAE-
C1-INH attacks brings about substantial reduction in
both direct and indirect costs, resulting in savings for
the National Health System and for the society as a
whole. To our knowledge and based on our literature
search, this is the first study to date that has evaluated
the economic costs involved in self-administration.
One of the strengths of the current study is that it
comprises all relevant variables impacting the cost of
managing acute HAE-C1-INH attacks, including the in-
direct costs related to patients’ and caretakers’ loss of
labour hours. Further, these indirect costs also account
for the years of life lost due to the unfortunate prema-
ture deaths which, though uncommon, do occur in this
patient population.
The main study limitation is the scant scientific evi-
dence available on the study variables. In the absence of
scientific evidence, the next best alternative to fill this in-
formation gap is the experts’ opinion. Although the panel
consisted of only two experts, they are both renowned
opinion leaders on this disease with ample experience in
the management of HAE-C1-INH in Spain. Another pos-
sible limitation of the study is that the costs of training pa-
tients to self-administer the treatment were not taken into
account. However, these costs would be irrelevant, since,in practice, the patients receive the training in the regular
visits to the specialist. Finally, the model assumes neither
underuse nor overuse of icatibant in the two compared
strategies. However, it would be possible that in some set-
tings, overuse or underuse may occur.
The alternative of self-administration of icatibant opens
the possibility of early treatment of acute attacks at the first
symptoms which may decrease attack severity [36,37]. For
instance, potentially severe attacks may turn into mild at-
tacks thanks to early treatment which is likely to lead to
even greater savings than those estimated in this study.
In addition, the unpredictability of the timing, fre-
quency, and severity of acute HAE-C1-INH attacks gener-
ate a substantial amount of stress in patients. Having the
means to control an acute attack quickly and effectively
may reduce that stress. This piece of mind compounds
another unquantifiable benefit such as the patient’s quality
of life improvement derived from the reduction of previ-
ous restrictions in daily activities as well as work and
school absenteeism [37,38].Conclusions
Both the clinical aspects of HAE-C1-INH and, now, the
economic aspects revealed in this study, strongly suggest
the need for targeted interventions. These interventions
would address home availability of the treatment specific
to acute attacks as proposed by national and inter-
national consensus [38-41] and HAE-C1-INH patients’
training on the proper technique of icatibant self-
administration.Abbreviations
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